Memantine;Memantina

Neurologia

Volumn 18, Issue 5, 2003, Pages 255-261

  Molinuevo, José L ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Alzheimer's disease; Memantine

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COGNITION; CONFUSION; CYSTITIS; DEMENTIA; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; REVIEW; RISK BENEFIT ANALYSIS; VERTIGO; VOMITING;

AGED; ALZHEIMER DISEASE; ANTIPARKINSON AGENTS; BRAIN; GLUTAMIC ACID; HUMANS; MEMANTINE;

EID: 0037591188     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400: 173-7.
2. Kilpatrick GJ, Tilbrook GS. Memantine. Curr Opin Investig Drugs 2002;3:798-806.
3. Danysz W, Parsons CG, Bresink I, Quack G. Glutamate in CNS disorders: a revived target for drug development? Drug News Perspect 1995;8:261-77.
4. Müller WE, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open channel kinetics and strong voltage dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry 1995;28:113-24.
5. Jain KK. Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs 2000;9:1397-406.
6. Danysz W, Parsons CG, Mobiüs HG, Stöfler A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease: a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000;2:85-97.
7. Rammsayer TH. Effects of pharmacologically induced changes in NMDA-receptor activity on long term memory in humans. Learn Mem 2001;8:20-5.
8. Thompson RF, Kim JJ. Memory systems in the brain and localization of a memory. Proc Natl Acad Sci USA 1996;93:13438-44.
9. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development. An update. Drugs News Perspect 1998;11:523-69.
10. Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor. Trends Neurosci 1987;10:299-302.
11. Li S, Mallory M, Aldford M, Tanaka S, Masliah E. Glutamate transporter alteration in Alzheimer's disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 1997;56:901-11.
12. Masliah E, Mallory M, Aldford M, Tanaka S, Hansen LA. Caspase dependent DNA fragmentation might be associated with excititoxicity in Alzheimer's disease. J Neuropathol Exp Neurol 1998;57:1041-52.
13. Arias C, Arrieta I and Tapia R. Beta amyloid peptide fragment potentiates the calcium dependent release of excitatory amino acids from depolarized hippocampal slices. J Neurosci Res 1995;41:561-6.
14. Wu JQ, Anwyl R, Rowan MJ. Beta amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hyppocampus. Neuroreport 1995;2409-13.
15. Couratier P, Sindou P, Tabarud E, Diop Ag, Spencer PS, Hugon J. Modulation of tau neuronal expression induced by NMDA, non-NMDA and metabotropic glutamate receptor agonists. Neurodegeneration 1995;4:33-41.
16. Sobolevsky A, Koshelev SG, Khorodov BI. Interaction of memantine and amantadine with agonist unbound NMDA receptor channels in acutely isolated rat hippocampal neurons. J Physiol 1998;512:47-60.
17. Parsons CG, Danysz W, Quack G. Memantine and the aminoalkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists. Amino Acids 2000;19:157-66.
18. Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 1993;33:403-7.
19. Berger W, Deckert J, Hartmann J, Krotzer C, Kornhuber J, Ransmayr G, et al. Memantine inhibits [3H]MK-801 binding to human hippocampal NMDA receptors. Neuroreport 1994 2;5:1237-40.
20. 2+ in hippocampal slices. Neuropharmacology 1999;38:1253-9.
21. Wenk GL, Zajaczkowski W, Danysz W. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res 1997;83:129-33.
22. Miguel-Hidalgo JJ, Alvarez XA, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 2002;958:210-21.
23. Barnes CA, Danysz W, Parsons CG. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal longterm potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 1996;8:565-71.
24. Zajaczkowski W, Quack G, Danysz W. Infusion of (+) -MK-801 and memantine contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996; 296:239-46.
25. Reisberg B, Windscheif U, Ferris SH, Stoeffler A, Moebious HJ and the Memantine Study Group. Memantine in moderately severe to severe Alzheimer's disease: results of a placebo controlled 6-month trial. Neurobiol Aging 2000;21(S):S1275.
26. Orgogozo JM, Rigaud AS, Stoeffler A, Moebious HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia. Stroke 2002;33:1834-9.
27. Göertelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome. Arzneimittelforschung 1992;42:904-13.
28. Pantev M, Ritter R, Göertelmeyer R. Clinical and behavioural evaluation in long term care patients with mild to moderate dementia under memantine treatment. Zeitschrift für Gentopsychologie und-Psychiatrie 1993;6:103-17.
29. Winblad B, Poritis N. Memantine in severe dementia: results of the M-best study (benefit and efficacy in severly demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-46.